Results from the trial will be presented at an upcoming medical meeting. “Pheochromocytoma and paraganglioma are rare tumors that form in and around the adrenal glands, and currently, there are no ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...

The First International Symposium on Pheochromocytoma, held in October 2005, included discussions about developments concerning these rare catecholamine-producing tumors. Recommendations were made ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

The US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to include its use for the treatment of the rare cancer pheochromocytoma and ...

Merck & Co (NYSE:MRK) said on Monday that the U.S. Food and Drug Administration (FDA) has granted priority review to its application for expanded use of the oral cancer drug Welireg.

and pheochromocytoma In the absence of data on specific therapies, management of orthostatic hypertension should be a function mainly of the condition of which it is a feature, and might include ...

Sweaty feet can be caused by several factors, from lifestyle and shoewear to medical conditions. Here are the potential ...

Industry giants like Takeda Pharmaceuticals, Pfizer, Novartis, and Bayer are revolutionizing treatment landscapes, paving the way for enhanced patien ...